In consideration of the accompany of gut microbiota changes, regulation of these bacteria and microenvironment may be the novel strategy for NAFLD therapy
Obesity or overweight is a serious health issue associated with some leading causes of death, including heart disease, stroke, and diabetes, and is linked to an increased risk of certain types of cancer
Symptoms may include a reduction in urine output, swelling in the legs or ankles, and feeling very tired
Key Market & Scientific Insights: A Watershed Moment: Recent studies show GLP-1s drive body-wide #rejuvenation through weight-neutral mechanisms, potentially reducing all-cause mortality in the US by 6.4% by 2045
We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity." References FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity
